Skip to main content

Nautilus Biotechnology, Inc.

NAUT
Exchange
Nasdaq
Industry
Laboratory Analytical Instruments
SEC CIK
0001808805

No open-market purchases or sales by Nautilus Biotechnology, Inc. insiders were filed in the last 90 days; 93 institutions reported holding it in 13F filings for Q2 2026, worth $93.7M in total; no superinvestor holds it.

Q2 2025 vs. Q1 2025

How the institutions holding Nautilus Biotechnology, Inc. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of NAUT: Q1 2025 compared with Q2 2025
MeasureQ1 2025Of which not filed for Q2 2025Q2 2025Change
Holders88171−16
Shares62.8M10.1K59.8M−3.01M (−4.8%)
Value$54.0M$8.69K$43.3M−$10.7M (−19.8%)

1 institution that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (12)

Institutions that held Nautilus Biotechnology, Inc. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to NAUT in Q2 2025
InstitutionSharesValue% of portfolio
Y-Intercept (Hong Kong) Ltd224,456$162.7K0.00%
MYDA Advisors LLC76,413$55.4K0.02%
Landscape Capital Management, L.L.C.71,301$51.7K0.00%
Cubist Systematic Strategies, LLC62,347$45.2K0.00%
Qube Research & Technologies Ltd62,138$45.0K0.00%
Callan Family Office, LLC48,894$35.4K0.00%
Jain Global LLC45,100$32.7K0.00%
Point72 Asia (Singapore) Pte. Ltd.32,577$23.6K0.00%
Ground Swell Capital, LLC20,061$14.5K0.02%
Point72 (DIFC) Ltd789$5720.00%
Essential Partners LLC23$170.00%
Simplex Trading, LLC115$00.00%

Sold out (28)

Institutions that held Nautilus Biotechnology, Inc. at the end of Q1 2025 and filed for Q2 2025 without it.

Not filed for Q2 2025 yet (1)

Institutions that held Nautilus Biotechnology, Inc. at the end of Q1 2025 and haven't filed a 13F for Q2 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NAUT in Q1 2025 that haven't filed for Q2 2025
InstitutionShares, Q1 2025Value, Q1 2025
CAPROCK Group, Inc.10,090$8.69K